TG Therapeutics Q2 Revenue Up 91%
TG Therapeutics (NASDAQ:TGTX), which specializes in treatments for autoimmune diseases, released its second-quarter 2025 earnings on August 4, 2025. The headline news was strong sales growth for BRIUMVI, its infusion therapy for relapsing multiple sclerosis, prompting management to raise its full-year 2025 revenue forecast. Revenue climbed to $138.8 million, missing the $137.98 million analyst estimate, while diluted earnings per share reached $0.17, below the expected $0.21. The quarter showed strong commercial progress but also highlighted sharply higher operating expenses tied to research, development, and marketing. Overall, the period underscored robust execution on BRIUMVI’s growth strategy, albeit with rising costs and continued heavy reliance on a single product.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
TG Therapeutics focuses on developing and commercializing therapies for B-cell mediated diseases, particularly relapsing forms of multiple sclerosis (RMS). Its central product, BRIUMVI, is an anti-CD20 monoclonal antibody delivered via intravenous infusion every 24 weeks. Approved by the Food and Drug Administration in December 2022, BRIUMVI is also cleared in the European Union, United Kingdom, Switzerland, and Australia.
Source Fool.com
